CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 9 of the 17 sources its claims cite were checked for support.
Abstract
BACKGROUND: . METHODS: After conducting preclinical in vitro and in vivo studies, we evaluated the safety and pharmacodynamic effects of single escalating doses of NTLA-2001 in six patients with hereditary ATTR amyloidosis with polyneuropathy, three in each of the two initial dose groups (0.1 mg per kilogram and 0.3 mg per kilogram), within an ongoing phase 1 clinical study. RESULTS: after a single dose. Serial assessments of safety during the first 28 days after infusion in patients revealed few adverse events, and those that did occur were mild in grade. Dose-dependent pharmacodynamic effects were observed. At day 28, the mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a dose of 0.1 mg per kilogram and was 87% (range, 80 to 96) in the group that received a dose of 0.3 mg per kilogram. CONCLUSIONS: . (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051.).
Overview
CoChat Summary
TL;DR
In six patients with hereditary ATTR amyloidosis with polyneuropathy, single intravenous doses of NTLA-2001, a CRISPR-Cas9 lipid nanoparticle therapy, produced dose-dependent reductions in serum TTR protein at day 28 and only mild adverse events. This interim phase 1 study provides early clinical proof of concept for in vivo CRISPR-Cas9 gene editing.
Key findings
- At day 28, mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the 0.1 mg/kg group and 87% (range, 80 to 96) in the 0.3 mg/kg group.
- Adverse events occurred in three of six patients and were all grade 1 (mild); no serious adverse events were observed. One patient had a grade 1 infusion-related reaction, and increased d-dimer levels in five of six patients returned to baseline by day 7.
- Preclinical studies showed durable TTR knockout after a single dose: in primary human hepatocytes, NTLA-2001 had EC50 0.05 to 0.15 nmol/L and EC90 0.17 to 0.67 nmol/L, with ≥93.7% TTR editing and ≥95% reduction in TTR protein production; in cynomolgus monkeys, a single dose of Cyn-LNP at 3 or 6 mg/kg produced maximum whole-liver gene editing of 73% and >94% reduction in serum TTR protein sustained over 12 months.
Methods
- Interim results from two initial dose groups of a two-part, global, phase 1, open-label, multicenter study: six patients with hereditary ATTR amyloidosis with polyneuropathy received a single intravenous dose of NTLA-2001 at 0.1 mg/kg or 0.3 mg/kg (three patients each) between November 2020 and April 2021.
- Key eligibility included age 18 to 80 years, polyneuropathy due to hATTR amyloidosis with or without cardiomyopathy, body weight 50 to 90 kg, and lack of access to approved ATTR treatments; prior TTR stabilizers were permitted after washout.
- Serum TTR protein was measured by validated enzyme-linked immunosorbent assay at baseline and weeks 1, 2, and 4; analyses were descriptive, comparing baseline with day 28 as mean percentage change and range. Preclinical work included primary human hepatocytes, transgenic mice, and cynomolgus monkeys.
Limitations
- The paper states that the study involves a very small number of patients with limited follow-up to date, and that continued serial measurements are planned to confirm durability. It also states that these are interim results from the first two dose groups in an ongoing dose-escalation study.
- Evident from the text: the clinical portion is open-label with no control group, uses descriptive analyses only, reports safety and pharmacodynamic effects through day 28, and does not report clinical outcomes such as disease progression, quality of life, or mortality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 1 Not valid · 5 Not checked · 56 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“TTR, which has a normal physiological role in vitamin A transport. 31”
What the sources say
- Supportedcites [31] 31. Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur J Heart Fail 2020; 22: 39-53. source
The Introduction states that TTR physiologically transports retinol-binding protein. The Therapeutic antisense oligonucleotides section links this function to vitamin A levels, supporting the paraphrase that TTR normally plays a role in vitamin A transport. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“but are limited by the requirement for long-term administration to maintain TTR knockdown.”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Trial Design and Regimens section reports patisiran infusions every three weeks for 18 months, and Pharmacodynamics reports sustained TTR reduction during that period. The paper does not establish that long-term administration is required to maintain knockdown after treatment stops, or that this limitation applies to current ATTR treatments generally. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [13] 13. Adams D, Polydefkis M, GonzálezDuarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an openlabel extension study. Lancet Neurol 2021; 20: 49-59. source
- Partly supportedcites [14] 14. Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139: 431-43. sourceExperimental — accuracy not yet measured
The Methods (Study Design and Treatment; page unavailable) report patisiran infusions every three weeks for 18 months, and the introductory passage describes its reduction of TTR protein. The paper does not establish that long-term administration is required to maintain TTR knockdown or characterize that requirement as a limitation of current ATTR treatments generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More extensive TTR knockdown is associated with greater improvement in neuropathic end points in patients with hATTR polyneuropathy. 12”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Primary End Point section reports a correlation between the degree of TTR reduction and change in mNIS+7, a composite neuropathy measure, at 18 months. The paper reports improvements in other end points, but our copy does not link the extent of knockdown to improvement across those end points. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“circulating TTR is produced almost entirely (>99%) within the liver, 2”
What the sources say
- Partly supportedcites [2] 2. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66: 2451-66. sourceExperimental — accuracy not yet measured
The section labeled “Diagnosis and Classification” says TTR is synthesized primarily in the liver, supporting the liver as its main source. It does not give the claimed >99% figure for circulating TTR. No page number is available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inotersen is associated with serious side effects, including glomerulonephritis and decreased platelet counts. 17”
What the sources say
- Supportedcites [17] 17. Gertz MA, Scheinberg M, Waddington-Cruz M, et al. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-medi- - ated amyloidosis. Expert Rev Clin Pharmacol 2019; 12: 701-11. source
The Safety and tolerability section (p. 9) reports decreased platelet counts and glomerulonephritis in patients receiving inotersen, including severe cases. The Regulatory affairs section (p. 9) states that the US approval carries a black box warning for increased risks of thrombocytopenia and glomerulonephritis. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
43 more claims · 1 with their cited sources checked
Create a free account to see all 69 claims and every source verdict.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“which has already lead to investigational new drugs in clinical trials (NCT04601051)”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Gillmore et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines (13, 14) that have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results (15–18).”
From Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease (2023) · cites this paper as [17]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationCRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Cited by
Items 601–700 of 1,725
Natural Biopolymer-Based Delivery of CRISPR/Cas9 for Cancer Treatment
Lin, M., & Wang, X. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010062 · Cited by 18
CRISPR /Cas gene editing and delivery systems for cancer therapy
Li, Y., Zhou, S., Wu, Q., & Gong, C. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1938 · Cited by 20
Pelizaeus–Merzbacher disease: on the cusp of myelin medicine
Elitt, M. S., & Tesar, P. J. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.03.005 · Cited by 16
Emerging mRNA Technology for Liver Disease Therapy
Wang, J., Fang, Y., Luo, Z., Wang, J., & Zhao, Y. (2024) · ACS Nano · doi:10.1021/acsnano.4c02987 · Cited by 21
Kansal, R. (2024) · Genes · doi:10.3390/genes15070863 · Cited by 22
“The in vivo aspect was achieved by lipid nanoparticles with hepatic specificity to deliver mRNA for Cas9 and single-guide RNA for TTR to hepatocytes [112].”
BackgroundEmerging lipid–polymer hybrid nanoparticles for genome editing
Gameiro, M. D., Mano, J. F., & Gaspar, V. M. (2024) · Polymer Chemistry · doi:10.1039/d4py00298a · Cited by 23
Cardiomyopathy: pathogenesis and therapeutic interventions
Huang, S., Li, J., Li, Q., Wang, Q., Zhou, X., Chen, J., Chen, X., Bellou, A., Zhuang, J., & Lei, L. (2024) · MedComm · doi:10.1002/mco2.772 · Cited by 25
Bairqdar, A., Karitskaya, P. E., & Stepanov, G. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413321 · Cited by 20
NANOSPRESSO: toward personalized, locally produced nucleic acid nanomedicines
Sentí, M. E., Ceccaldi, A., Luciani, M., Saber, N., Schürmann, P. J. L., Geerlings, M. W., Hölig, P., de Beer, J., Hannus, M., Campbell, F., et al. (2025) · Frontiers in Science · doi:10.3389/fsci.2025.1458636 · Cited by 19
“Recent developments in DNA editing are now entering clinical trials and expanding the toolkit for genetic intervention, including CRISPR/Cas9 and the newer Cas13, which makes temporary RNA edits (38) (Figure 3) (39 – 42).”
Lipid nanoparticle formulation for gene editing and RNA-based therapies for glioblastoma
Zhang, Y., Rabinovsky, R., Deforzh, E., Kobayashi, A., Kuzkina, A., Varghese, J. F., Rai, D., Korecka, J. A., Khurana, V., Murugaiyan, G., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf162 · Cited by 22
“39 31 We compared MC3, SM-102, and LP01 and found that LP01-based LNPs effectively and selectively target GSCs in vitro and in vivo, showing broad Cas9 distribution mainly in GBM tissues with minimal brain parenchyma expression, enhancing precision and reducing off-target risks.”
Glycolipid nanoparticles target the spleen and detarget the liver without charge
Gentry, K., Lian, L., Kim, H., Celik, O., Jones, C., Podilapu, A. R., Shakked, A., Loughrey, D., Zenhausern, R., Jang, B., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2409569122 · Cited by 18
In vivo targeting of a variant causing vanishing white matter using CRISPR/Cas9
Hillen, A. E. J., Hruzova, M., Rothgangl, T., Breur, M., Bugiani, M., van der Knaap, M. S., Schwank, G., & Heine, V. M. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.02.006 · Cited by 17
Neurological update: hereditary neuropathies
Kramarz, C., & Rossor, A. M. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11164-1 · Cited by 17
“Vol.:(0123456789) Keywords Charcot–Marie–tooth disease · SORD-associated CMT · PMP22 gene silencing · SPTLC1-associated HSN1 · ATTR amyloidosis”
BackgroundInfluentialFSHD Therapeutic Strategies: What Will It Take to Get to Clinic?
Himeda, C. L., & Jones, P. L. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060865 · Cited by 21
“In the one in vivo clinical trial of CRISPR gene editing to date, it is encouraging that no significant safety concerns were reported in the six patients at 28 days post-treatment [85].”
BackgroundGantz, V. M., & Bier, E. (2022) · BioEssays · doi:10.1002/bies.202100279 · Cited by 17
Gene Editing to Tackle Facioscapulohumeral Muscular Dystrophy
Mariot, V., & Dumonceaux, J. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.937879 · Cited by 17
“The interim data published recently showed the first clinical evidence that CRISPR gene editing could be done effectively inside the body and without major safety problems (Gillmore et al., 2021; Therapeutics, 2022).”
BackgroundIn vivo application of base and prime editing to treat inherited retinal diseases
Jo, D. H., Bae, S., Kim, S., Kim, J., & Kim, J. H. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101132 · Cited by 17
Huang, C., Li, Q., & Li, J. (2022) · Medical Review · doi:10.1515/mr-2022-0029 · Cited by 20
“3mg per kilogram at 28 dpi, even thoughmild adverse effects were observed [219].”
BackgroundDelivery challenges for CRISPR—Cas9 genome editing for Duchenne muscular dystrophy
Padmaswari, M. H., Agrawal, S., Jia, M. S., Ivy, A., Maxenberger, D. A., Burcham, L. A., & Nelson, C. E. (2023) · Biophysics Reviews · doi:10.1063/5.0131452 · Cited by 19
Truong, L. B., Medina-Cruz, D., & Mostafavi, E. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125185 · Cited by 18
Fulfilling the Promise of RNA Therapies for Cardiac Repair and Regeneration
Giacca, M. (2023) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szad038 · Cited by 15
Emerging and potential use of CRISPR in human liver disease
Adlat, S., Vázquez-Salgado, A. M., Lee, M., Yin, D., & Wangensteen, K. J. (2025) · Hepatology · doi:10.1097/hep.0000000000000578 · Cited by 21
Advances and Challenges in the Development of Gene Therapy Medicinal Products for Rare Diseases
Bueren, J. A., & Auricchio, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.152 · Cited by 17
Quaternization drives spleen-to-lung tropism conversion for mRNA-loaded lipid-like nanoassemblies
Huang, Y., Wu, J., Li, S., Liu, Z., Li, Z., Zhou, B., & Li, B. (2024) · Theranostics · doi:10.7150/thno.90071 · Cited by 17
Kimura, N., Tanaka, Y., Yamanishi, Y., Takahashi, A., & Sakuma, S. (2024) · ACS Nano · doi:10.1021/acsnano.3c07461 · Cited by 16
Greco, F., Cosentino, M., & Marino, F. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1356578 · Cited by 21
“The design of a CRISPR/Cas9 treatment system that is delivered by lipid nanoparticles, termed “NTLA-2001,” reduced transthyretin levels by around 87%, with mild adverse effects in 3 of the 6 patients treated (34).”
BackgroundA Comparison of Amyloid Deposition in Endoscopic and Open Carpal Tunnel Release.
Ozdag, Y., Koshinski, J. L., Carry, B., Gardner, J. M., Garcia, V. C., Dwyer, C. L., Akoon, A., Klena, J., & Grandizio, L. C. (2024) · Journal of Hand Surgery-American Volume · doi:10.1016/j.jhsa.2024.01.002 · Cited by 13
The Diagnostic and Therapeutic Implications of Phenocopies and Mimics of Hypertrophic Cardiomyopathy
Bakalakos, A., Monda, E., & Elliot, P. M. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.02.025 · Cited by 20
Mantri, P., Juneja, B., Henderson, S., Koufos, E., Moon, Y., Dayeh, D. M., Grandi, D. D., Fu, Y., Muthusamy, K., Ihnat, P. M., et al. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116352 · Cited by 17
Emerging Gene-editing nano-therapeutics for Cancer
Nujoom, N., Koyakutty, M., Biswas, L., Rajkumar, T., & Nair, S. V. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39323 · Cited by 20
Outpatient Worsening of Heart Failure and Mortality in Transthyretin Amyloid Cardiomyopathy
Zeldin, L., Eichler, J., Teruya, S. L., Weinsaft, A., Mirabal, A., Cuomo, M., Mateo, K., Helmke, S. T., & Maurer, M. S. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3540 · Cited by 20
Boosting Lipofection Efficiency Through Enhanced Membrane Fusion Mechanisms
Pavlov, R. V., Akimov, S. A., Dashinimaev, E. B., & Bashkirov, P. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413540 · Cited by 17
Razvi, Y., Porcari, A., Hutt, D. F., et al. (2025) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2025.03.014 · Cited by 15
Self-citationFuture Perspectives of Oral Delivery of Next Generation Therapies for Treatment of Skin Diseases
Søgaard, P. P., Lind, M. L., Christiansen, C. R., Petersson, K., Clauss, A., & Caffarel–Salvador, E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101722 · Cited by 15
“Nevertheless, a recent phase I study has shown a promising safety profile for in vivo editing of the transthyretin (TTR) gene for the treatment of transthyretin amyloidosis (ATTR) [29].”
BackgroundMethodInfluentialCurrent Advances Toward the Encapsulation of Cas9
Kanduri, V., LaVigne, D., & Larsen, J. (2021) · ACS Macro Letters · doi:10.1021/acsmacrolett.1c00538 · Cited by 14
Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays
Kaku, M. C., Bhadola, S., Berk, J. L., Sanchorawala, V., Connors, L. H., & Lau, K. H. V. (2022) · Amyloid · doi:10.1080/13506129.2022.2046557 · Cited by 15
“The emergence of disease-altering therapeutics including TTR protein stabilisers and RNA-interference agents [4] alongside early potential of gene therapy [5] has led to urgency in both earlier diagnosis of disease and timely recognition of onset of disease activity among genetic carriers.”
BackgroundEngineered exosomes for future gene-editing therapy.
Guo, H., & Huang, X. (2022) · PubMed Central · doi:10.12336/biomatertransl.2022.04.003 · Cited by 20
Viral and nonviral nanocarriers for in vivo CRISPR-based gene editing
Guo, Z., Zhu, A. T., Fang, R. H., & Zhang, L. (2024) · Nano Research · doi:10.1007/s12274-024-6748-5 · Cited by 18
Yin, S., Gao, L., Sun, X., Zhang, M., Gao, H.-Y., Chen, X., Zhang, D., Ming, X., Yang, L., Hu, Y., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.032 · Cited by 14
Hereditary transthyretin amyloidosis (ATTRv)
Triposkiadis, F. K., Briasoulis, Α., Starling, R. C., Magouliotis, D. E., Kourek, C., Zakynthinos, G. Ε., Iliodromitis, E. K., PARASKEVAIDIS, I. A., & Xanthopoulos, A. V. (2025) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2025.103019 · Cited by 16
Tailored therapeutics for cardiomyopathies
Bakalakos, A., Monda, E., & Elliot, P. M. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01183-6 · Cited by 16
“Nexiguran ziclumeran, a CRISPR–Cas9-based gene therapy, has been evaluated in a phase I trial involving patients with ATTRv-related polyneuropathy, demonstrating a sustained reduction in plasma TTR levels, with a favourable safety profile 202 .”
Meerasa, S. S., Ahmad, A., Khan, A. A., Haque, S., & Saleem, I. Y. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126263 · Cited by 15
Modern Strategies of Drug Therapy: Multi-Target Drug Delivery, Bioimaging, Diagnostics
Fedorova, O. V., Ovchinnikova, I. G., Rusinov, G. L., Avdeeva, V. V., Zhdanov, А. P., Zhizhin, K. Y., Kuznetsov, N. T., Zakharova, L. Y., Kuznetsova, D. A., Razuvayeva, Y. S., et al. (2025) · Russian Journal of General Chemistry · doi:10.1134/s1070363225606726 · Cited by 18
Navigating the next frontier in biomedicine: breakthroughs and insights in nucleic acid therapeutics
Wu, S., Zhang, Z., Zhao, Z., Cui, C., & Tan, W. (2026) · Chemical Science · doi:10.1039/d5sc06966a · Cited by 22
“170 This therapy utilizes lipid nano-particles (LNPs) to co-deliver mRNA encoding Streptococcus pyogenes Cas9 (SpCas9) together with an sgRNA targeting the transthyretin (TTR) gene, thereby achieving precise knockout of the TTR gene in patients' hepatocytes.”
Mechanistic and Therapeutic Insights into Ataxic Disorders with Pentanucleotide Expansions
Zhang, N., & Ashizawa, T. (2022) · Cells · doi:10.3390/cells11091567 · Cited by 14
Lu, Z. H., Li, J., Dmitriev, I. P., Kashentseva, E. A., & Curiel, D. T. (2022) · ACS Nano · doi:10.1021/acsnano.2c00909 · Cited by 14
Pinto, M. V., França, M. C., Gonçalves, M. V. M., Costa, M. C. M., de Freitas, M. R., Gondim, F. D. A. A., Marrone, C. D., Martínez, A., Moreira, C. L., Nascimento, O. J. M., et al. (2023) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0043-1764412 · Cited by 20
“116 This approach has the potential to treat all forms of ATTR amyloidosis — both wild-type and hereditary disease, and as it is only a single dose, treatment compliance would not be an issue.”
Guri, I., Alrokh, Y., Kim, Y., Maeshima, R., Graham, C., Hart, S. L., McGrath, J. A., & Jackow, J. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad528 · Cited by 21
“80 This trial is a major milestone, marking the first use of in vivo gene editing in humans.”
BackgroundmRNA biotherapeutics landscape for rare genetic disorders
Iyer, V. R., Praveen Reddy., P., Kaduskar, B., Moharir, S. C., & Mishra, R. K. (2024) · Journal of Biosciences · doi:10.1007/s12038-023-00415-6 · Cited by 19
“NTLA 2001 is a one-shot therapy designed to target hepatocytes where it knocks out the mutant TTR gene and, as a result, decreases the production of the mutant TTR protein and the associated cytotoxicity (Gillmore et al .”
State of Gene Therapy for Monogenic Cardiovascular Diseases
Bains, S., Giudicessi, J. R., Odening, K. E., & Ackerman, M. J. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.11.003 · Cited by 16
Gene editing in common cardiovascular diseases
Lauerer, A.-M., Caravia, X. M., Maier, L. S., Chemello, F., & Lebek, S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108720 · Cited by 15
Healy, L., Giblin, G. T., Gray, A., Starr, N., Murphy, L., O'Sullivan, D., Kavanagh, E. C., Howley, C., Tracey, C., Morrin, E., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15112 · Cited by 19
Molecular Manipulations and Intestinal Stem Cell-Derived Organoids in Inflammatory Bowel Disease
Boye, T. L., Steenholdt, C., Jensen, K. B., & Nielsen, O. H. (2022) · Stem Cells · doi:10.1093/stmcls/sxac014 · Cited by 14
Müthel, S., Marg, A., Ignak, B., Kieshauer, J., Escobar, H., Stadelmann, C., & Spuler, S. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.02.005 · Cited by 16
“The feasibility of LNP-based delivery of mRNA has been shown impressively by the recent success of mRNA vaccines against SARS-CoV2(53) and the first clinical trial of systemic CRISPR-Cas9 in vivo genome editing.(54)”
BackgroundPulmonary alveolar proteinosis – current and future therapeutical strategies
Jehn, L.-B., & Bonella, F. (2023) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000982 · Cited by 15
Correction of Fanconi Anemia Mutations Using Digital Genome Engineering
Sipe, C. J., Kluesner, M. G., Bingea, S. P., Lahr, W. S., Andrew, A. A., Wang, M., DeFeo, A. P., Hinkel, T., Laoharawee, K., Wagner, J. E., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158416 · Cited by 18
“Most of these studies involve the use of recombinant adeno-associated vectors (rAAVs) [45], the HDAd5/35++ vector [46], or lipid-like nanoparticles (LLNPs) [47] to package and deliver CRISPR-Cas9 and related reagents to target cells.”
BackgroundGenetic therapies and potential therapeutic applications of CRISPR activators in the eye
Ng, B., Kaukonen, M. K., McClements, M. E., Shamsnajafabadi, H., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101289 · Cited by 14
Kulhánková, K., Cheng, A. X., Traore, S., Auger, M., Pelletier, M., Hervault, M., Wells, K. D., Green, J. A., Byrne, A. K., Nelson, B., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae819 · Cited by 15
“Despite tremendous clinical advances ex vivo ( 48 ), targeting somatic cells in vivo beyond the eye ( 49 ) and liver ( 50 ) remains challenging ( 16 ,17 ).”
BackgroundHan, X., Xu, Y., Ricciardi, A. S., Xu, J., Xiang, Y., Palanki, R., Chowdhary, V., Xue, L., Gong, N., Alameh, M., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2528144123 · Cited by 18
Self-citationEngineering adeno-associated viral vectors for CRISPR/Cas based in vivo therapeutic genome editing
Moyo, B., Brown, L. B. C., Khondaker, I., & Bao, G. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123314 · Cited by 13
RNA–lipid nanoparticles for acute critical illnesses
Omo‐Lamai, S., Zamora, M. E., Mueller, B. K., Casciano, J. C., & Brenner, J. S. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00314-5 · Cited by 18
Recent Advances in mRNA-LNP Delivery Systems for Extrahepatic Organs: A Review
Bai, Y., Cui, L., Liu, T., Wang, Z., Cao, H., He, S., Qiu, J., Li, Y., Zhou, Y., Shi, J., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00385 · Cited by 27
Muto, H., Kubara, K., Hitaoka, S., Osada, Y., & Suzuki, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114055 · Cited by 20
CRISPR delivery systems for organ-specific targeting: Advances and challenges
Du, J., Wu, Q., Liu, C., Wang, N., & Gong, C. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100048 · Cited by 21
Bharti, N., Modi, U., Bhatia, D. D., & Solanki, R. (2026) · Nanoscale Advances · doi:10.1039/d5na00535c · Cited by 16
Lipid-Based Colloidal Nanocarriers for Site-Specific Drug Delivery
Shameli, K., Kalali, B. N., Moeini, H., & Kartouzian, A. (2026) · Colloids and Interfaces · doi:10.3390/colloids10010007 · Cited by 15
Targeted delivery of genome editors in vivo
Ngo, W., Wu, J. L. Y., Wasko, K. M., & Doudna, J. A. (2026) · Nature Biotechnology · doi:10.1038/s41587-025-02945-w · Cited by 22
“For example, NTLA-2001, an LNP formulated with Cas9 messenger RNA (mRNA) and single-guide RNA (sgRNA), is administered intravenously and capable of reducing serum transthyretin protein levels by up to 87% in patients after 28 d to treat transthyretin amyloidosis (NCT04601051) 7 .”
Non-Viral CRISPR carriers: transient delivery with lasting effects
Lummerstorfer, M., & Lächelt, U. (2026) · Drug Delivery · doi:10.1080/10717544.2026.2614125 · Cited by 19
“Based on the success of commercial LNP formulations, the technology has been applied analogously for delivery of CRISPR RNA (Cas9-encoding mRNA and sgRNA) (Gillmore et al. 2021).”
Rurik, J. G., & Epstein, J. A. (2022) · DNA and Cell Biology · doi:10.1089/dna.2022.0171 · Cited by 13
Opportunities for Earlier Diagnosis and Treatment of Cardiac Amyloidosis
Martyn, T., Rubio, A. C., Estep, J. D., & Hanna, M. A. (2022) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1163 · Cited by 14
Advanced Nanomedicine for High-Risk HPV-Driven Head and Neck Cancer
Xu, Q., Chen, Y., Jin, Y., Wang, Z., Dong, H., Kaufmann, A. M., Albers, A. E., & Qian, X. (2022) · Viruses · doi:10.3390/v14122824 · Cited by 14
“The interim results from the first clinical trial with lipid nanoparticles as delivery vectors for CRISPR/Cas9 demonstrated successful knockout of the targeted gene with only mild adverse effects for the treatment of hereditary transthyretin amyloidosis with polyneuropathy [86].”
BackgroundStability Criterion for the Assembly of Core–Shell Lipid–Polymer–Nucleic Acid Nanoparticles
Paris, J. L., Gaspar, R., Coelho, F., Beule, P. D., & Silva, B. F. B. (2023) · ACS Nano · doi:10.1021/acsnano.3c07204 · Cited by 16
Madu, E. C., & Mezue, K. N. (2023) · BMC Global and Public Health · doi:10.1186/s44263-023-00016-3 · Cited by 17
Unlocking the potential of RNA-based therapeutics in the lung: current status and future directions
Man, H. S. J., Moosa, V. A., Singh, A. N., Wu, L., Granton, J. T., Juvet, S., Hoang, C. D., & de Perrot, M. E. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1281538 · Cited by 15
Next-generation biological vector platforms for in vivo delivery of genome editing agents
Leclerc, D., Siroky, M. D., & Miller, S. M. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103040 · Cited by 17
Gene editing therapy for cardiovascular diseases
Wu, X., Yang, J., Zhang, J., & Song, Y. (2024) · MedComm · doi:10.1002/mco2.639 · Cited by 17
RNA encoded peptide barcodes enable efficient in vivo screening of RNA delivery systems
Odunze, U., Rustogi, N., Devine, P., Miller, L., Pereira, S. G. T., Vashist, S., Snijder, H. J., Corkill, D. J., Sabirsh, A., Douthwaite, J. A., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae648 · Cited by 19
Khan, S., Bano, N., Ahamad, S., Dar, N. J., Nazir, A., & Bhat, S. A. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216206 · Cited by 14
Desai, D. A., Schmidt, S., & Cristofoletti, R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1454785 · Cited by 17
Garcia, D. A., Pierre, A. F., Quirino, L., Acharya, G., Vasudevan, A., Pei, Y., Chung, E., Chang, J. Y. H., Lee, S., Endow, M., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.020 · Cited by 17
“28 We propose the use of TALENmRNAs totargetthe LPA gene invivo using LUNAR, a proprietary LNP-based mRNA delivery platform.”
Tissue-specific modulation of CRISPR activity by miRNA-sensing guide RNAs
Garcia-Guerra, A., Sathyaprakash, C., de Jong, O. G., Lim, W. F., Vader, P., Andaloussi, S. E., Bath, J., Reiné, J., Aoki, Y., Turberfield, A. J., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf016 · Cited by 15
Koyra, N., Yu, H., Drummond, C. J., Zhai, J., & Dyett, B. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2518225 · Cited by 16
Genome editing technology and applications with the type I CRISPR system
Yoshimi, K., & Mashimo, T. (2022) · Gene and Genome Editing · doi:10.1016/j.ggedit.2022.100013 · Cited by 24
Gene Editing — A Cure for Transthyretin Amyloidosis?
Maurer, M. S. (2021) · New England Journal of Medicine · doi:10.1056/nejme2110557 · Cited by 13
Xu, X., Cui, L., Zhang, Y., & Gu, J. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.11.023 · Cited by 13
Kwok, C. S., & Moody, W. (2023) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/17539447231216318 · Cited by 15
Versatile Cell Penetrating Peptide for Multimodal CRISPR Gene Editing in Primary Stem Cells
Graham, J. P., Castro, J. G., Werba, L. C., Amitrano, J., Fardone, L. C., Francis, K. P., Ramamurthi, A., Layden, M. J., McCarthy, H. O., & Gonzalez‐Fernandez, T. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202501532 · Cited by 19
“Lipid-based strategies have attracted much attention due to their use in mRNA vaccines and have been employed across multiple CRISPR applications [23, 24, 25, 26].”
In vivo nano-engineering T cells for CAR-T therapy
Shi, T., Li, Y., Deng, C., Ren, Q., Xu, C., & Zhong, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114379 · Cited by 20
Qiu, X., Yang, Y., Ma, Q., Zheng, B., Chen, Z., Wu, F., Zhou, B., & Xiong, H. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c19387 · Cited by 16
Quantitative and qualitative comparison of mRNA loading techniques into extracellular vesicles
Guarro, M., van Veen, S., Borrós, S., Albertazzi, L., Lecina, M., & Fornaguera, C. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118813 · Cited by 16
Genetic strategies for therapy of Duchenne muscular dystrophy
Łoboda, A., Chamberlain, J. S., & Dulak, J. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102759 · Cited by 20
“Systemic non-viral delivery has already been applied for the treatment of transthyretin amyloidosis, 211 demonstrating its feasibility.”
Moore, S. T., Lian, X., Vaidya, A., Chatterjee, S., Santelli, J., Sun, Y., Farbiak, L., Zhu, H., & Siegwart, D. J. (2026) · Nature Communications · doi:10.1038/s41467-025-68103-7 · Cited by 24
Gong, L., Liu, X., Wu, J., & He, M. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01292-x · Cited by 11
“editing in a small group of patients with hereditary ATTR amyloidosis with polyneuropathy [20].”
BackgroundKulcsár, P. I., Tálas, A., Ligeti, Z., Tóth, E., Rakvács, Z., Bartos, Z., Krausz, S. L., Welker, Á., Végi, V. L., Huszár, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41393-5 · Cited by 15
Terapia génica para la insuficiencia cardiaca y las miocardiopatías
Argirò, A., Ding, J., & ADLER, E. D. (2023) · Revista Española de Cardiología · doi:10.1016/j.recesp.2023.06.016 · Cited by 13
de Assis, A. J. B., Santana, B. L. D. O., Gualberto, A. C. M., & Pittella-Silva, F. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1322937 · Cited by 16
Bhatia, S. N., & Dahlman, J. E. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2315789121 · Cited by 12
Assembling the RNA therapeutics toolbox
Teng, M., Xia, Z. J., Lo, N., Daud, K., & He, H. H. (2024) · Medical Review · doi:10.1515/mr-2023-0062 · Cited by 13
“For example, NTLA-2001 is an in vivo gene editing agent composed of LNP encapsulating Cas9 mRNA and sgRNA targeting transthyretin (TTR) for the treatment of transthyretin amyloidosis [99].”
BackgroundThree-dimensional cardiac models: a pre-clinical testing platform
Groen, E., Mummery, C. L., Yiangou, L., & Davis, R. P. (2024) · Biochemical Society Transactions · doi:10.1042/bst20230444 · Cited by 14
Current concepts of the crosstalk between lncRNA and E2F1: shedding light on the cancer therapy
Huang, P., Wen, F., & Li, Q. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1432490 · Cited by 14
Metadata
- Authors
- Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., Kyratsous, C. A., Zambrowicz, B., Soltys, R., Gutstein, D. E., Leonard, J., Sepp-Lorenzino, L., & Lebwohl, D.
- Affiliations
- University of Auckland (NZ)
- From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George’s University of London (J.T.) — both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) — all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 493-502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177445623
- Cited by
- 1,801
- References
- 35
- Citations by year
- 2026: 349 · 2025: 332 · 2024: 368 · 2023: 336 · 2022: 328 · 2021: 84
- FWCI
- 228.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Intellia Therapeutics
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- transthyretin amyloidosis, hereditary ATTR amyloidosis, CRISPR/Cas9 genome editing, in vivo gene therapy, prealbumin, polyneuropathy, single ascending dose, pharmacodynamics, safety
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Female, Humans, Infusions, Intravenous, Liposomes, Male, Middle Aged, Prealbumin, RNA, Messenger, RNA, Guide, Kinetoplastida, Gene Transfer Techniques, Amyloid Neuropathies, Familial, Nanoparticles, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.



